Bliss GVS is proud of its segment leadership in Anti-malarial products across most African markets. Our brands cover an extensive range of Artemisinin-based combination formulations across various dosage forms – Tablets, Suspensions, Suppositories and Injections. Lonart is our flagship brand for Artemether & Lumefantrine combination, the fixed-dose recommended & pre-qualified by WHO for the treatment of uncomplicated malaria caused by plasmodium falciparum
Over the last decade, we have expanded our portfolio to include a wider range of products across different therapeutic segments in order to cater to the increasing demands from countries in which we operate. In the dermatology segment, our Funbact brand is now prominent in the anti-fungal segment. To facilitate growth in this area, we have also added to our manufacturing capabilities in creams, ointments and gels. We are also rapidly building our manufacturing capabilities in herbal sore throat lozenges, a segment in which we have seen very high growth over the last few years. Thus, with significant expansion in R & D, Manufacturing & Marketing capabilities, we are poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.